OpenURL Connection Search

Select item for more details and to access through your institution.

Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia.
Published in:
2011
By:
- Yoshida, Chikashi;
- Komeno, Takuya;
- Hori, Mitsuo;
- Kimura, Tomofumi;
- Fujii, Masami;
- Okoshi, Yasushi;
- Suzukawa, Kazumi;
- Chiba, Shigeru;
- Hasegawa, Yuichi;
- Mukai, Harumi;
- Ito, Takayoshi;
- Shimizu, Seiichi;
- Kamoshita, Masaharu;
- Kudo, Daisuke;
- Shinagawa, Atsushi;
- Chikatsu, Norio;
- Monma, Yuriko;
- Watanabe, Norimichi;
- Kojima, Hiroshi;
- Mukai, Harumi Yamamoto
Publication type:
journal article
Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study).
Published in:
2018
By:
- Nakasone, Hideki;
- Terasako‐Saito, Kiriko;
- Hirano, Teiichi;
- Wake, Atsushi;
- Shimizu, Seiichi;
- Kurita, Naoki;
- Yamazaki, Etsuko;
- Usuki, Kensuke;
- Akazawa, Kohei;
- Kanda, Junya;
- Minauchi, Koichiro;
- Yamamoto, Go;
- Tanimoto, Shiori;
- Kamoshita, Masaharu;
- Yokoyama, Yasuhisa;
- Miyaoka, Etsuo;
- Ota, Shuichi;
- Kako, Shinichi;
- Izutsu, Koji;
- Kanda, Yoshinobu
Publication type:
journal article
Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.
Published in:
Acta Haematologica, 2015, v. 134, n. 1, p. 25, doi. 10.1159/000369445
By:
- Cho, Yukiko;
- Hori, Mitsuo;
- Okoshi, Yasushi;
- Fujisawa, Fumie;
- Shinagawa, atsushi;
- Kudo, Daisuke;
- Komeno, Takuya;
- Yoshida, Chikashi;
- Katsura, Yukitaka;
- Ota, Ikuyo;
- Shimizu, Seiichi;
- Kamoshita, Masaharu;
- Sasaki, Katsuhiro;
- Tanaka, Keiji;
- Mukai, Harumi Y.;
- Kojima, Hiroshi
Publication type:
Article
Megakaryopoiesis in patients with cyclic thrombocytopenia.
Published in:
British Journal of Haematology, 1995, v. 91, n. 1, p. 185, doi. 10.1111/j.1365-2141.1995.tb05267.x
By:
- Nagasawa, Toshiro;
- Hasegawa, Yuichi;
- Kamoshita, Masaharu;
- Ohtani, Kouji;
- Komeno, Takuya;
- Itoh, Takayoshi;
- Shinagawa, Atsushi;
- Kojima, Hiroshi;
- Ninomiya, Haruhiko;
- Abe, Tsukasa
Publication type:
Article

Found: 4

Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia.

Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study).

Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.

Megakaryopoiesis in patients with cyclic thrombocytopenia.